TBK1 regulates prostate cancer dormancy through mTOR inhibition

Neoplasia (United States)

Volumn 15, Issue 9, 2013, Pages 1064-1074

  Kim, Jin Koo ^a   Jung, Younghun ^a   Wang, Jingcheng ^a   Joseph, Jeena ^a   Mishra, Anjali ^a   Hill, Elliott E ^a   Krebsbach, Paul H ^a   Pienta, Kenneth J ^b   Shiozawa, Yusuke ^a   Taichman, Russell S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; HERMES ANTIGEN; I KAPPA B KINASE EPSILON; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PHOSPHOTRANSFERASE; RAPAMYCIN; TANK BINDING KINASE 1; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; DORMANCY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84897123138     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.13402     Document Type: Article

References (56)

1. Kawai T and Akira S (2011). Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34, 637-650.
2. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, and Hiscott J (2003). Triggering the interferon antiviral response through an IKK-related pathway. Science 300, 1148-1151.
3. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, and Maniatis T (2003). IKKe{open} and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 4, 491-496.
4. Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, Kawai T, Hoshino K, Takeda K, and Akira S (2004). The roles of two IκB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 199, 1641-1650.
5. Perry AK, Chow EK, Goodnough JB, Yeh WC, and Cheng G (2004). Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J Exp Med 199, 1651-1658.
6. Shen RR and Hahn WC (2011). Emerging roles for the non-canonical IKKs in cancer. Oncogene 30, 631-641.
7. Baldwin AS (2012). Regulation of cell death and autophagy by IKK and NF-κB: critical mechanisms in immune function and cancer. Immunol Rev 246, 327-345.
8. Korherr C, Gille H, Schäfer R, Koenig-Hoffmann K, Dixelius J, Egland KA, Pastan I, and Brinkmann U (2006). Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 103, 4240-4245.
9. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, Balakireva MG, Romeo Y, Kopelovich L, Gale M Jr, et al. (2006). RalB GTPase-mediated activation of the IκB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-170.
10. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112.
11. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, Brekken R, Wurz R, Tasker A, Polverino T, et al. (2011). TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 41, 458-470.
12. Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, Wang CY, and Guan KL (2011). IκB kinase e{open} and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 108, 6474-6479.
13. Zoncu R, Efeyan A, and Sabatini DM (2011). mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21-35.
14. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, and Sabatini DM (2002). mTOR interacts with raptor to form a nutrientsensitive complex that signals to the cell growth machinery. Cell 110, 163-175.
15. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J, and Yonezawa K (2003). The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278, 15461-15464.
16. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, and Slingerland JM (2008). mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30, 701-711.
17. Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, and Hall MN (2004). Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 1122-1128.
18. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, and Sabatini DM (2006). mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16, 1865-1870.
19. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, and Sabatini DM (2006). Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168.
20. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
21. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, and Lane HA (2009). Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 8, 742-753.
22. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al. (2011). Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121, 1298-1312.
23. Wilson A, Laurenti E, and Trumpp A (2009). Balancing dormant and selfrenewing hematopoietic stem cells. Curr Opin Genet Dev 19, 461-468.
24. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, et al. (2007). Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079.
25. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, and Cantley LC (2009). Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKe{open} promotes cell transformation. Mol Cell 34, 461-472.
26. Parmar K, Mauch P, Vergilio JA, Sackstein R, and Down JD (2007). Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci USA 104, 5431-5436.
27. Rehn M, Olsson A, Reckzeh K, Diffner E, Carmeliet P, Landberg G, and Cammenga J (2011). Hypoxic induction of vascular endothelial growth factor regulates murine hematopoietic stem cell function in the low-oxygenic niche. Blood 118, 1534-1543.
28. Rankin EB, Wu C, Khatri R, Wilson TL, Andersen R, Araldi E, Rankin AL, Yuan J, Kuo CJ, Schipani E, et al. (2012). The HIF signaling pathway in osteoblasts directly modulates erythropoiesis through the production of EPO. Cell 149, 63-74.
29. Ranganathan AC, Adam AP, Zhang L, and Aguirre-Ghiso JA (2006). Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells? Cancer Biol Ther 5, 729-735.
30. Vessella RL, Pantel K, and Mohla S (2007). Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 6, 1496-1504.
31. Quesnel B (2008). Dormant tumor cells as a therapeutic target? Cancer Lett 267, 10-17.
32. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. (2004). MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 431, 1112-1117.
33. Felsher DW (2008). Tumor dormancy and oncogene addiction. APMIS 116, 629-637.
34. Wikman H, Vessella R, and Pantel K (2008). Cancer micrometastasis and tumour dormancy. APMIS 116, 754-770.
35. MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12, 863-879.
36. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M, and Scadden DT (2000). Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 287, 1804-1808.
37. Gan B and DePinho RA (2009). mTORC1 signaling governs hematopoietic stem cell quiescence. Cell Cycle 8, 1003-1006.
38. Chen C, Liu Y, Liu R, Ikenoue T, Guan KL, Liu Y, and Zheng P (2008). TSCmTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. J Exp Med 205, 2397-2408.
39. Gan B, Sahin E, Jiang S, Sanchez-Aguilera A, Scott KL, Chin L, Williams DA, Kwiatkowski DJ, and DePinho RA (2008). mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci USA 105, 19384-19389.
40. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H, and Morrison SJ (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441, 475-482.
41. Zhang J, Grindley JC, Yin T, Jayasinghe S, He XC, Ross JT, Haug JS, Rupp D, Porter-Westpfahl KS, Wiedemann LM, et al. (2006). PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. Nature 441, 518-522.
42. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, et al. (2008). Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 22, 986-991.
43. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, and Pandolfi PP (2008). PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072-1078.
44. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, Fletcher-Sananikone E, Colla S, Wang YA, Chin L, et al. (2010). Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468, 701-704.
45. Gurumurthy S, Xie SZ, Alagesan B, Kim J, Yusuf RZ, Saez B, Tzatsos A, Ozsolak F, Milos P, Ferrari F, et al. (2010). The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 468, 659-663.
46. Nakada D, Saunders TL, and Morrison SJ (2010). Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature 468, 653-658.
47. Castilho RM, Squarize CH, Chodosh LA, Williams B, and Gutkind JS (2009). mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 5, 279-289.
48. Basith S, Manavalan B, Yoo TH, Kim SG, and Choi S (2012). Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res 35, 1297-1316.
49. González-Reyes S, Fernández JM, González LO, Aguirre A, Suárez A, González JM, Escaff S, and Vizoso FJ (2011). Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol Immunother 60, 217-226.
50. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, and Riccioli A (2008). Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-α-dependent mechanism. Carcinogenesis 29, 1334-1342.
51. Laplante M and Sabatini DM (2012). mTOR signaling in growth control and disease. Cell 149, 274-293.
52. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, et al. (2008). The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118, 3917-3929.
53. Ghosh S, Tergaonkar V, Rothlin CV, Correa RG, Bottero V, Bist P, Verma IM, and Hunter T (2006). Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-κB activation and cell survival. Cancer Cell 10, 215-226.
54. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, et al. (2009). mTOR signal and hypoxiainducible factor-1α regulate CD133 expression in cancer cells. Cancer Res 69, 7160-7164.
55. Yang Z, Zhang L, Ma A, Liu L, Li J, Gu J, and Liu Y (2011). Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 6, e28405.
56. Hoshii T, Tadokoro Y, Naka K, Ooshio T, Muraguchi T, Sugiyama N, Soga T, Araki K, Yamamura K, and Hirao A (2012). mTORC1 is essential for leukemia propagation but not stem cell self-renewal. J Clin Invest 122, 2114-2129.